No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
OEC240719P27500
- 5.09
- 0.000.00%
15min DelayTrading Feb 28 12:41 ET
0.00High0.00Low
0.00Open5.09Pre Close0 Volume0 Open Interest27.50Strike Price0.00Turnover1381.34%IV4.54%PremiumJul 19, 2024Expiry Date4.03Intrinsic Value100Multiplier-3DDays to Expiry1.07Extrinsic Value100Contract SizeAmericanOptions Type-0.8962Delta0.0562Gamma4.61Leverage Ratio-7.4649Theta0.0000Rho-4.13Eff Leverage0.0004Vega
Intraday
- 5D
- Daily
News
Orion Innovation Nombra a Cyrus Lam Como Director Financiero
Orion (NYSE:OEC) Will Want To Turn Around Its Return Trends
Orion S.A. Announces Second Quarter 2024 Earnings Release Date and Conference Call Information
Is Now The Time To Look At Buying Orion S.A. (NYSE:OEC)?
Is Orion S.A. (NYSE:OEC) Expensive For A Reason? A Look At Its Intrinsic Value
Moody's Affirms Orion Ratings on Market Position, Operating Profitability
Comments
Orion is undervalued compared to peers, with high volatility presenting buying opportunities. Optimistic future earnings could boost cash flows and share value, but financial health is also crucial.
Is Orion S.A. (NYSE:OEC) Potentially Undervalued? 1
Gainers:
• $Revlon(REV.US$ +81% (Reliance mulling buyout of REV according to Economic Times)
• $United States Steel(X.US$ +6.4% (issues upside EPS guidance),
• $Ellington Financial(EFC.US$ +5% (reports book value per share)
• $Aurora Mobile(JG.US$ +4.9% (receives RMB15 mln in special support funding from the Shenzhen Development and Reform Commission)
• $Citi Trends(CTRN.US$ +4.4% (names new CFO)
• $Roku Inc(ROKU.US$ +4.2% (ROKU an...
• $Revlon(REV.US$ +81% (Reliance mulling buyout of REV according to Economic Times)
• $United States Steel(X.US$ +6.4% (issues upside EPS guidance),
• $Ellington Financial(EFC.US$ +5% (reports book value per share)
• $Aurora Mobile(JG.US$ +4.9% (receives RMB15 mln in special support funding from the Shenzhen Development and Reform Commission)
• $Citi Trends(CTRN.US$ +4.4% (names new CFO)
• $Roku Inc(ROKU.US$ +4.2% (ROKU an...
12
Gainers:
• $Clovis Oncology(CLVS.US$ +40.6% (Rubraca significantly improves progression-free survival in first-line maintenance treatment in women with ovarian cancer regardless of their biomarker status in phase 3 athena-mono trial)
• $Dare Bioscience(DARE.US$ +13.61% (Organon and Dar Bioscience have entered into an agreement whereby Organon will license global rights to XACIATO)
• $KULR Technology(KULR.US$ +9.5% (secured a battery sa...
• $Clovis Oncology(CLVS.US$ +40.6% (Rubraca significantly improves progression-free survival in first-line maintenance treatment in women with ovarian cancer regardless of their biomarker status in phase 3 athena-mono trial)
• $Dare Bioscience(DARE.US$ +13.61% (Organon and Dar Bioscience have entered into an agreement whereby Organon will license global rights to XACIATO)
• $KULR Technology(KULR.US$ +9.5% (secured a battery sa...
14
Read more